biomarker-guided-therapy

Biomarker-Guided Therapy in Neurodegenerative Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">biomarker-guided-therapy</th>
</tr>
<tr>
<td class="label">Biomarker Combination</td>
<td>Clinical Application</td>
</tr>
<tr>
<td class="label">p-tau217 + Aβ42/40 + NfL + GFAP</td>
<td>AD screening, staging, and prognosis</td>
</tr>
<tr>
<td class="label">alpha-synuclein SAA + DAT-SPECT + GBA1 genotype</td>
<td>PD subtype classification and trial matching</td>
</tr>
<tr>
<td class="label">NfL + SOD1/C9orf72 genetics + muscle biomarkers</td>
<td>ALS diagnosis, subtyping, and therapy selection</td>
</tr>
<tr>
<td class="label">[Amyloid PET](/entities/amyloid-pet) + tau PET + MRI volumetrics + [APOE](/proteins/apoe-protein) genotype</td>
<td>Comprehensive AD staging for treatment planning</td>
</tr>
</table>

Introduction

Overview

...

Biomarker-Guided Therapy in Neurodegenerative Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">biomarker-guided-therapy</th>
</tr>
<tr>
<td class="label">Biomarker Combination</td>
<td>Clinical Application</td>
</tr>
<tr>
<td class="label">p-tau217 + Aβ42/40 + NfL + GFAP</td>
<td>AD screening, staging, and prognosis</td>
</tr>
<tr>
<td class="label">alpha-synuclein SAA + DAT-SPECT + GBA1 genotype</td>
<td>PD subtype classification and trial matching</td>
</tr>
<tr>
<td class="label">NfL + SOD1/C9orf72 genetics + muscle biomarkers</td>
<td>ALS diagnosis, subtyping, and therapy selection</td>
</tr>
<tr>
<td class="label">[Amyloid PET](/entities/amyloid-pet) + tau PET + MRI volumetrics + [APOE](/proteins/apoe-protein) genotype</td>
<td>Comprehensive AD staging for treatment planning</td>
</tr>
</table>

Introduction

Overview

Biomarker-guided therapy is an emerging precision medicine approach that uses measurable biological indicators — from blood, cerebrospinal fluid (CSF), neuroimaging, or genetic testing — to guide treatment selection, dosing, timing, and monitoring in neurodegenerative diseases. Rather than treating all patients with the same diagnosis identically, biomarker-guided approaches stratify patients by their specific molecular and pathological profile, enabling targeted interventions matched to individual disease biology [@hansson2025]. [@hansson2025]

The 2024 revision of the NIA-AA diagnostic criteria for [Alzheimer's disease](/diseases/alzheimers-disease) marked a paradigm shift, formally defining AD by its biological markers rather than clinical symptoms alone. This transition from syndromic to biological diagnosis sets the stage for biomarker-guided therapeutic decision-making analogous to precision oncology [@jack2024]. [@jack2024]

Key Biomarker Categories

Blood-Based Biomarkers

Blood-based biomarkers have transformed the field by enabling minimally invasive, scalable disease detection and monitoring: [@palmqvist2024]

• Phosphorylated [tau](/proteins/tau) (p-tau217, p-tau181): Highly specific for [Alzheimer's disease](/diseases/alzheimers-disease) amyloid and [tau](/proteins/tau) pathology. [p-tau217](/biomarkers/p-tau-217) performs comparably to CSF biomarkers and amyloid PET for identifying amyloid-positive individuals [@palmqvist2024]
• [Amyloid-Beta](/proteins/amyloid-beta) ratio ([Aβ42](/proteins/amyloid-beta)/40): Decreased plasma Aβ42/40 ratio correlates with cerebral amyloid burden
• [Neurofilament light chain (NfL)](/proteins/nfl-protein): A general marker of neuronal injury and axonal damage, elevated in [ALS](/diseases/als), [FTD](/diseases/ftd), [multiple sclerosis](/diseases/multiple-sclerosis), and advanced AD [@khalil2018]
• [GFAP](/entities/gfap) (Glial Fibrillary Acidic Protein): Marker of [astrocyte](/cell-types/astrocytes) reactivity, elevated early in AD
• [alpha-synuclein](/proteins/alpha-synuclein) seed amplification assay (SAA): Detects misfolded [alpha-synuclein](/proteins/alpha-synuclein) in CSF and blood, diagnostic for [Parkinson's disease](/diseases/parkinsons-disease) and [Lewy body dementia](/diseases/lewy-body-dementia)

CSF Biomarkers

• CSF Aβ42, p-[tau](/proteins/tau), total tau: The "AD CSF signature" — decreased Aβ42 with increased p-tau and t-tau
• CSF [NfL](/proteins/nfl-protein)): Neuronal damage marker used in clinical trials for ALS and FTD
• CSF [TREM2](/proteins/trem2-protein): Soluble [TREM2](/proteins/trem2-protein) reflects [microglial](/cell-types/microglia)
• [MAPT](/proteins/mapt-protein) testing: Identifies tau-mutant FTD patients eligible for tau-targeted therapeutics](/therapeutics/tau-targeted-therapeutics)
• CSF [NfL](/proteins/nfl-protein): Prognostic biomarker and clinical trial endpoint

Multi-Biomarker Profiles

Novel Biomarker-Guided Therapy Approaches

The following novel therapy approaches use specific biomarkers for patient selection, dosing, and efficacy monitoring:

NfL-Guided Neuroprotection

• Target: [Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NfL)
• Approach: Reduce axonal injury via neuroprotective interventions
• Page: [NfL-Guided Neuroprotection Therapy](/ideas/nfl-guided-neuroprotection-therapy)

Tau PET-Guided Tau Immunotherapy

• Target: Tau PET imaging, CSF p-tau
• Approach: Anti-tau antibodies with PET-monitored dosing
• Page: [Tau PET-Guided Tau Immunotherapy](/ideas/tau-pet-guided-tau-immunotherapy)

Alpha-Synuclein Seed Amplification Therapy

• Target: RT-QuIC, CSF alpha-synuclein
• Approach: Clear misfolded alpha-synuclein aggregates
• Page: [Alpha-Synuclein Seed Amplification Therapy](/ideas/alpha-synuclein-seed-amplification-therapy)

GFAP-Guided Astrocyte Modulation

• Target: GFAP, YKL-40, S100B
• Approach: Normalize astrocyte activation and neuroinflammation
• Page: [GFAP-Guided Astrocyte Modulation Therapy](/ideas/gfap-astrocyte-modulation-therapy)

DNA Damage Repair Therapy

• Target: 8-OHdG, gamma-H2AX, PAR levels
• Approach: Enhance DNA repair mechanisms
• Page: [DNA Damage Repair Therapy - Biomarker Guided](/ideas/dna-damage-repair-therapy)

Modern [precision medicine](/therapeutics/precision-medicine-neurodegeneration) approaches increasingly use multi-biomarker panels rather than single markers: [@khalil2018]

A "combinatorial strategy" integrating blood-based biomarkers, neuroimaging, and genetic data is increasingly viewed as the most realistic approach for individualized treatment planning [@teunissen2022].

Biomarker-Guided Clinical Trial Design

Biomarkers have transformed clinical trial design in neurodegeneration:

• Enrichment: Selecting biomarker-positive participants (e.g., amyloid-PET-positive for AD trials) increases the probability of detecting treatment effects
• Stratification: Randomizing participants by biomarker profile (e.g., [APOE](/proteins/apoe-protein) genotype) ensures balanced groups
• Surrogate endpoints: Biomarker changes (amyloid clearance, NfL reduction) serve as accelerated approval endpoints
• Adaptive designs: Biomarker data guides dose selection, population enrichment, and early futility analysis during trials
• Basket trials: Testing therapies across diseases unified by a common biomarker (e.g., NfL-positive neurodegeneration)

Regulatory Landscape

• FDA accelerated approval has been granted based on biomarker endpoints: [lecanemab](/therapeutics/lecanemab) (amyloid clearance as surrogate), [tofersen](/therapeutics/tofersen) (NfL reduction as surrogate)
• The 2024 NIA-AA criteria establish biomarker-defined AD as the standard for clinical research
• Blood-based biomarkers are being validated for regulatory use as pre-screening tools, reducing the need for expensive PET scans

Challenges

Access and equity: PET scans cost $5,000–$8,000; blood tests may democratize access if validated and approved

Standardization: Different assay platforms yield different results; reference standards needed

Pre-symptomatic treatment: Biomarkers detect disease years before symptoms — ethical implications of early diagnosis and treatment

Multi-pathology: Many patients have mixed pathologies (AD + Lewy body + vascular); single-disease biomarkers may miss co-existing conditions

Dynamic monitoring: Biomarker levels change over disease course and with treatment — establishing trajectories requires longitudinal data

See Also

• [Neurodegenerative Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Combination Therapy Approaches in Neurodegenerative Disease](/therapeutics/combination-therapy)
• [Donanemab (Kisunla)](/therapeutics/donanemab)
• [Lecanemab (Leqembi)](/therapeutics/lecanemab)
• [Neuroprotection Strategies in Neurodegeneration](/therapeutics/neuroprotection)
• [Precision Medicine in Neurodegeneration](/therapeutics/precision-medicine-neurodegeneration)
• [Tofersen](/therapeutics/tofersen)

External Links

• [NIA-AA 2024 Revised Criteria for AD](https://www.nia.nih.gov/)
• [Alzheimer's Biomarkers — Alzforum](https://www.alzforum.org/biomarkers)
• [ADNI (Alzheimer's Disease Neuroimaging Initiative)](https://adni.loni.usc.edu/)

Background

The study of Biomarker Guided Therapy In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Unknown, Hansson O. "Biomarker-guided decision making in clinical drug development for neurodegenerative disorders." Nat Rev Drug Discov. 2025. [DOI (2025)](https://doi.org/10.1038/s41573-025-01165-w)

[Jack CR Jr, et al., "Revised criteria for diagnosis and staging of Alzheimer's Disease." Alzheimers Dement. 2024;20(8):5633-5667. [DOI (2024)](https://doi.org/10.1002/alz.13859)

[Palmqvist S, et al., "Blood biomarkers to detect Alzheimer's Disease in primary care and secondary care." JAMA. 2024;332(15):1245-1257. [DOI (2024)](https://doi.org/10.1001/jama.2024.13855)

[Khalil M, et al., "Neurofilaments as biomarkers in neurological disorders." Nat Rev Neurol. 2018;14(10):577-589. [DOI (2018)](https://doi.org/10.1038/s41582-018-0058-z)

[Sperling RA, et al., "Association of factors with elevated amyloid burden in clinically normal older individuals." JAMA Neurol. 2020;77(6):735-745. [DOI (2020)](https://doi.org/10.1001/jamaneurol.2020.0387)

[Miller TM, et al., "Trial of antisense oligonucleotide tofersen for SOD1 ALS." N Engl J Med. 2022;387(12):1099-1110. [DOI (2022)](https://doi.org/10.1056/NEJMoa2204705)

[van Dyck CH, et al. ", Lecanemab in early Alzheimer's Disease." N Engl J Med. 2023;388(1):9-21. [DOI (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Teunissen CE, et al., "Blood-based biomarkers for Alzheimer's Disease: towards clinical implementation." Lancet Neurol. 2022;21(1):66-77. [DOI (2022)](https://doi.org/10.1016/S1474-4422(21)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE

Related Analyses:

• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;